
Home / Clinics Supported / Hormone Optimization
Hormone replacement therapy for men and women under one roof: TRT, BHRT and the lab monitoring around them. ACG helps you open an independent clinic for one audience or both. No medical background is required to own the business; an independent, state-licensed Medical Director directs all clinical care.
Book a Strategy CallU.S. searches for “bioidentical hormones” run 1,000 to 10,000 a month (Google Keyword Planner), and one hormone optimization clinic can serve men's and women's demand alike.
In many markets the nearest hormone provider is a telehealth company, whose testosterone prescribing without an in-person exam rests on a DEA rule that runs through December 31, 2026. Our program to start a wellness clinic helps you open the local alternative, with in-office labs and no franchise royalties.
A patient whose labs are monitored by a provider who knows their baseline can stay enrolled for years. That relationship drives lifetime value in cash-pay hormone care.
Google Keyword Planner, U.S., Sep 2025 to Aug 2026, in the ranges Google reports. “Hormone replacement therapy” and “HRT for women” return no figure. Local demand varies by market.
Testosterone is a Schedule III controlled substance, while BHRT turns on compounding pharmacy vetting: different patients, protocols and compliance exposure. Each has its own full clinic model.
Testosterone replacement therapy, lab monitoring and prescriber-directed adjuncts such as sermorelin, with DEA-ready prescribing for your state.
Bioidentical hormone replacement plus menopause and perimenopause care, with FDA-approved or compounded options chosen by your Medical Director.
Testosterone is a controlled substance, compounded hormones need careful pharmacy vetting, and prescribing authority varies by state. Our team has navigated this across hundreds of clinic launches.
Testosterone is Schedule III. Registration, prescribing structure and record-keeping are sequenced for your state, with a plan for the December 31, 2026 telemedicine deadline.
ACG introduces vetted Medical Directors through partner networks in all 50 states and coordinates the oversight agreement.
Pre-vetted pharmacy partners at preferred pricing. Compounded bioidentical hormones are not FDA-approved, so your Medical Director weighs them against approved options.
Patient intake, informed consent and clinical protocols, set with your Medical Director before the first patient walks in.
You own and run the business; an independent, state-licensed Medical Director directs all clinical care. ACG plans each step with you.
Demand, competitors and positioning in your market, before you commit capital.
Entity setup, state licensing, DEA registration and a Medical Director introduction, sequenced for your state.
Compounding pharmacy partners, EMR, lab panels and protocols, set with your Medical Director.
Hormone clinic advertising has platform restrictions. ACG plans a marketing strategy that fits them; execution is a separate engagement.
Grand opening planning and 60 days of post-launch advisory.
Straight answers on prescribers, compounded hormones, state rules and serving men and women. Anything else, ask on the strategy call.
View All FAQs
The hormone clinic in your market may still be waiting to be built. Talk with Grayson Miller about local demand, serving men, women or both, and what opening takes. No pitch. No obligation.
ACG is a consulting and advisory firm, not a medical practice; an independent, state-licensed Medical Director directs all clinical care. Results are not guarantees of income. Individual outcomes vary. The 60-day target begins from clinic keys received, market and regulatory conditions permitting.
Knowing the rules is the foundation of every clinic we help launch.
You own and run the business. An independent, state-licensed Medical Director makes every clinical, prescribing and treatment decision, structured for your state's Corporate Practice of Medicine laws. We connect you to a vetted network; you retain your own provider.
PRP, peptides, GLP-1 medications and cellular products each carry federal and state rules, and not every product or use is FDA-approved. Exosomes for therapeutic use are not FDA-approved at all, and we steer you away from them. Your menu and marketing are built to hold up to FDA, FTC and state medical board scrutiny.
We show real ranges and never promise an income or a clinical outcome. What you earn depends on your market, your capital and your execution.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe or sell any drug, biologic, device or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the compliance of every product, therapy and claim. See the full regulatory notice below.